Updates are available Correction dated 2022-03-08
Click to view Correction: https://doi.org/10.1007/s10147-022-02118-8
-
Authors
Tsubata, Yukari https://orcid.org/0000-0002-4260-2849
Watanabe, Kana
Saito, Ryota
Nakamura, Atsushi
Yoshioka, Hiroshige
Morita, Mami
Honda, Ryoichi
Kanaji, Nobuhiro
Ohizumi, Satoshi
Jingu, Daisuke
Nakagawa, Taku
Nakazawa, Kensuke
Mouri, Atsuto
Takeuchi, Susumu
Furuya, Naoki
Akazawa, Yuki
Miura, Kiyotaka
Ichihara, Eiki
Maemondo, Makoto
Morita, Satoshi
Kobayashi, Kunihiko
Isobe, Takeshi
-
Funding
Funding for this research was provided by:
astrazeneca
- License Information
-
More Information
Article History
Received: 16 June 2021
Accepted: 28 September 2021
First Online: 13 October 2021
Change Date: 8 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10147-022-02118-8
Declarations
:
: Y.T. received grants and personal fees from Daiichi Sankyo Co. Ltd. and AstraZeneca K.K. and personal fees from Chugai Pharmaceuticals Inc. outside the submitted work. A.N. received personal fees and research funding (institution) from AstraZeneca K.K., Chugai Pharmaceuticals Inc., MSD K.K., and Taiho Pharmaceutical; personal fees from Nippon Boehringer Ingelheim Co. Ltd. and Novartis Pharma K.K.; and research funding (institution) from Ono Pharmaceutical, Bristol-Myers Squibb, Pfizer, Takeda Pharmaceutical, and Astellas Pharma Inc. outside the submitted work. H.Y. received personal fees from AstraZeneca K.K., Chugai Pharmaceuticals Inc., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Taiho Pharmaceutical, Ono Pharmaceutical, Delta-Fly Pharma, Inc., Bristol-Myers Squibb Company, Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Nippon Kayaku Co., Ltd., and Eli Lilly Japan K.K. outside the submitted work. S.O. received grants from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Kissei Pharmaceutical, Ono Pharmaceutical, Pfizer, Merck Biopharma, Sanofi, Taiho Pharmaceutical, and Takeda Pharmaceutical, and personal fees from AstraZeneca K.K. and Eli Lilly outside the submitted work. N.F. received personal fees from AstraZeneca K.K., Chugai Pharmaceutical, Nippon Boehringer Ingelheim Co. Ltd., Bristol-Myers Squibb Company, Eli Lilly Japan K.K., MSD K.K., Pfizer Japan Inc. Taiho Pharmaceutical, and Novartis Pharma K.K. outside the submitted work. E.I. received personal fees from AstraZeneca K.K. and Nippon Boehringer Ingelheim Co. Ltd. outside the submitted work. M.M. received personal fees from AstraZeneca K.K., Nippon Boehringer Ingelheim Co. Ltd., Chugai Pharmaceutical Co. Ltd., and Pfizer Japan Inc. outside the submitted work. S.M. received honoraria from AstraZeneca K.K., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., and Taiho Pharmaceutical Co. Ltd; advisory fees from Astellas Pharma Inc.; and research funding (institution) from Nippon Boehringer Ingelheim Co. Ltd. outside the submitted work. K.K. received personal fees from AstraZeneca K.K., Bristol-Myers Squibb, and Nippon Boehringer Ingelheim Co. Ltd. outside the submitted work. T.I. received grants and personal fees from Daiichi Sankyo Co. Ltd; personal fees from AstraZeneca K.K., Pfizer Japan Inc., and Nippon Boehringer Ingelheim Co., Ltd.; and grants from Pearl Therapeutics Inc. outside the submitted work.
